Lv1
25 积分 2022-02-18 加入
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2个月前
已完结
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
5个月前
已关闭
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
5个月前
已完结
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
5个月前
已完结
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
5个月前
已完结
Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease
6个月前
已完结
Comprehensive Treatment Approaches To Obesity
6个月前
已关闭
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial
8个月前
已完结
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
8个月前
已完结
皖公网安备34019202002308
